Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hercules plus taxane versus Herceptin plus taxane in first-line HER2-positive metastatic breast cancer
2011-001965-42Phase 3Terminated
- Sponsor
- Mylan
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trastuzumab in breast cancer (2 arms), sponsored by Mylan. Primary endpoint: Best overall response rate. Started Sep 2012; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-001965-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001965-42.